A bioluminescent mouse model of pancreatic β-cell carcinogenesis

Carcinogenesis

Volumn 31, Issue 8, 2010, Pages 1465-1474

  Zumsteg, Adrian ^a   Strittmatter, Karin ^a   Klewe Nebenius, Daniela ^a   Antoniadis, Helena ^a   Christofori, Gerhard ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FIREFLY LUCIFERASE; MESSENGER RNA; VIRUS LARGE T ANTIGEN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CANCER MODEL; CARCINOGENESIS; DISTANT METASTASIS; EX VIVO STUDY; FEMALE; GENE EXPRESSION; GENETIC MANIPULATION; IN VIVO STUDY; INSULINOMA; MALE; MICROMETASTASIS; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREATIC BETA CELL CARCINOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SIMIAN VIRUS; TRANSGENIC MOUSE; TUMOR LOCALIZATION;

ANIMALS; APOPTOSIS; CARCINOMA, ISLET CELL; CELL DIVISION; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; INSULIN-SECRETING CELLS; LUCIFERASES; LUMINESCENCE; MICE; MICE, TRANSGENIC; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA;

EID: 77955374412     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq109     Document Type: Article

References (38)

1. Hanahan,D. et al. (2007) The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer. Genes Dev., 21, 2258-2270.
2. Hanahan,D. (1985) Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature, 315, 115-122.
3. Hanahan,D. et al. (2000) The hallmarks of cancer. Cell, 100, 57-70.
4. Folkman,J. et al. (1989) Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature, 339, 58-61.
5. Inoue,M. et al. (2002) VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell, 1, 193-202.
6. Bergers,G. et al. (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol., 2, 737-744.
7. Christofori,G. et al. (1994) A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature, 369, 414-418.
8. Perl,A.K. et al. (1998) A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature, 392, 190-193.
9. Zumsteg,A. et al. (2009) Corrupt policemen: inflammatory cells promote tumor angiogenesis. Curr. Opin. Oncol., 21, 60-70.
10. Nozawa,H. et al. (2006) Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc. Natl Acad. Sci. USA, 103, 12493-12498.
11. Wild,D. et al. (2006) [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J. Nucl. Med., 47, 2025-2033.
12. Schomber,T. et al. (2009) Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis. Mol. Cancer Ther., 8, 55-63.
13. Shojaei,F. et al. (2008) Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc. Natl Acad. Sci. USA, 105, 2640-2645.
14. Wicki,A. et al. (2007) [Lys40(Ahx-DTPA-111In)NH2]-exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptortargeted therapy for insulinoma. Clin. Cancer Res., 13, 3696-3705.
15. Bergers,G. et al. (1999) Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science, 284, 808-812.
16. Compagni,A. et al. (2000) Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res., 60, 7163-7169.
17. Casanovas,O. et al. (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell, 8, 299-309.
18. Parangi,S. et al. (1996) Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc. Natl Acad. Sci. USA, 93, 2002-2007.
19. Dietrich,W.F. et al. (1994) Genome-wide search for loss of heterozygosity in transgenic mouse tumors reveals candidate tumor suppressor genes on chromosomes 9 and 16. Proc. Natl Acad. Sci. USA, 91, 9451-9455.
20. Grant,S.G. et al. (1991) Early invasiveness characterizes metastatic carcinoid tumors in transgenic mice. Cancer Res., 51, 4917-4923.
21. Taketo,M. et al. (1991) FVB/N: an inbred mouse strain preferable for transgenic analyses. Proc. Natl Acad. Sci. USA, 88, 2065-2069.
22. Gannon,G. et al. (2002) Overexpression of vascular endothelial growth factor-A165 enhances tumor angiogenesis but not metastasis during betacell carcinogenesis. Cancer Res., 62, 603-608.
23. Kopfstein,L. et al. (2007) Distinct roles of vascular endothelial growth factor-D in lymphangiogenesis and metastasis. Am. J. Pathol., 170, 1348-1361.
24. Lopez,T. et al. (2002) Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell, 1, 339-353.
25. Mandriota,S.J. et al. (2001) Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J., 20, 672-682.
26. Perl,A.K. et al. (1999) Reduced expression of neural cell adhesion molecule induces metastatic dissemination of pancreatic beta tumor cells. Nat. Med., 5, 286-291.
27. Crnic,I. et al. (2004) Loss of neural cell adhesion molecule induces tumor metastasis by up-regulating lymphangiogenesis. Cancer Res., 64, 8630-8638.
28. Wykoff,C. et al. (2000) Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res., 60, 7075-7083.
29. Weber,H.C. et al. (1995) Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology, 108, 1637-1649.
30. Kopfstein,L. et al. (2006) Metastasis: cell-autonomous mechanisms versus contributions by the tumor microenvironment. Cell. Mol. Life Sci., 63, 449-468.
31. Jackson,D.G. et al. (2001) LYVE-1, the lymphatic system and tumor lymphangiogenesis. Trends Immunol., 22, 317-321.
32. Schledzewski,K. et al. (2006) Lymphatic endothelium-specific hyaluronan receptor LYVE-1 is expressed by stabilin-1+, F4/80+, CD11b+ macrophages in malignant tumours and wound healing tissue in vivo and in bone marrow cultures in vitro: implications for the assessment of lymphangiogenesis. J. Pathol., 209, 67-77.
33. Mouta Carreira,C. et al. (2001) LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and downregulation in human liver cancer and cirrhosis. Cancer Res., 61, 8079-8084.
34. Coussens,L.M. et al. (2000) MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell, 103, 481-490.
35. Hirshberg,B. et al. (2005) Malignant insulinoma: spectrum of unusual clinical features. Cancer, 104, 264-272.
36. Paez-Ribes,M. et al. (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell, 15, 220-231.
37. Thiery,J. et al. (2006) Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol., 7, 131-142.
38. Denardo,D. et al. (2009) CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell, 16, 91-102.